Pricing Log in Create free account
Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

45.65 1.11 +2.49%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alkermes plc 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 9:20 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 28, 2026: 3 added · 2 removed · 22 modified; 17 with only figures updated; 1 moved without change

  1. Modified · Executive Summary

    Net income was $0.516.3 million or $0.000.10 per ordinary share—basic and $0.09 per ordinary share—diluted, for the three months ended JuneSeptember 30, 2026 and net loss was $66.049.7 million or $0.400.30 per ordinary share—basic and diluted, for the sixnine months ended JuneSeptember 30, 2026, compared to net income of $87.182.8 million and $109.6192.3 million or $0.530.50 and $0.671.17 per ordinary share—basic and $0.520.49 and $0.651.14 per ordinary share—diluted, for the three and sixnine months ended JuneSeptember 30, 2025, respectively.

26 more changes in this Item, word by word, in Powerpack.